Inge jedema, PhD

Head translational cellular therapy
Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Netherlands

Presentation(s):

• 61: Surgical considerations for tumor-infiltrating lymphocyte (TIL) therapy in melanoma: results from a randomized phase 3 trial.

  Thursday, March 21, 2024
  2:07pm – 2:17pm ET